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Abstract 
Ibogaine,  a putatively anti-addictive  alkaloid,  binds  to K-opioid  and  NMDA  receptors.  In the present  study  we investigated  the roles  of 
K-opioid and NMDA  actions  in mediating  ibogaine’s  (40 mg/kg,  i.p.>  behavioral  and neurochemical  effects  in rats. A combination  of a 
K-opioid antagonist (norbinaltorphimine, 10 mg/kg,  s.c.) and a  NMDA  agonist (NMDA,  20  mg/kg,  i.p.> partially  prevented 
ibogaine-induced  inhibition of intravenous  morphine  self-administration  and ibogaine-induced  antagonism  of morphine-induced  locomo- 
tor stimulation. The combination,  as well as norbinaltorphimine  and NMDA  alone,  blocked  the acute  effects of ibogaine  on dopamine 
release  and metabolism  in the striatum.  The data  suggest  that both K-opioid  agonist  and  NMDA antagonist  actions  of ibogaine  contribute 
to its putative  anti-addictive  effects. 
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Ibogaine, an alkaloid extracted from  Tabemanthe  iboga, 
is  being  studied  as a potential  long-acting  treatment for 
both  opioid  and  stimulant  abuse. While  there have been 
only  anecdotal  reports  of  long-term  efficacy  in  humans, 
e.g.,  [17],  studies  in  this  [4,6]  and other  [l]  laboratories 
have shown that ibogaine can decrease  both morphine and 
cocaine  self-administration  for  several days in  some rats; 
similar  effects  are produced by  noribogaine, a metabolite 
of  ibogaine  [5].  Acutely,  ibogaine  and  noribogaine  de- 
crease  extracellular  levels  of  dopamine  in  the  nucleus 
accumbens and striatum while  ibogaine pretreatment (19 h 
beforehand) blocks morphine-induced dopamine release  [8] 
and morphine-induced  hyperactivity  [9,14].  Because both 
ibogaine  and its  metabolite  noribogaine bind  to  K-opioid, 
e.g., [3,13,16] and NMDA  receptors, e.g., [11,15], we have 
been investigating  the roles of  K-opioid and NMDA  mech- 
anisms in mediating ibogaine’s behavioral and neurochem- 
ical  effects.  The  interactions  of  a  K-opioid  antagonist 
(nor-binaltorphimine,  norBN1)  and/or  a  NMDA  agonist 
(iV-methyl-D-aspartic  acid,  NMDA)  with  ibogaine  were 
assessed in  terms  of  three of  ibogaine’s  reported effects: 
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inhibition  of morphine self-administration  [6], inhibition  of 
morphine-induced motor  stimulation  [9,14],  and inhibition 
of  dopamine (DA)  release in  the striatum  [Xl. The resul: 
of  these studies suggest that  both  K-agonist and NMDA 
antagonist actions of  ibogaine  and noribogaine  contribute 
to, but may not entirely  account for,  the resultant effects. 
All  subjects  were  naive  female  Sprague-Dawley 
(Taconic, Germantown, NY)  rats, approximately  3 months 
old  and  weighing  230-250  g  at  the  beginning  of  an 
experiment. Rats were maintained on a normal  light/dark 
cycle (lights  on/off  at 07.00 h/19.00  h). 
The intravenous self-administration  procedure has been 
described  previously,  e.g.,  [4,6].  Briefly,  responses  on 
either  of  two  levers  (mounted  1.5 cm  apart  on  the  front 
wall  of each operant test cage) were recorded on an IBM 
compatible 486 computer with  a Med Associates interface. 
The  intravenous  self-administration  system  consisted  of 
polyethylene-silicone  cannulas  constructed  according  to 
the design of Weeks [21], Instech harnesses  and commuta- 
tors,  and  Harvard  Apparatus  infusion  pumps  (No.  55- 
2222).  Shaping  of  the  bar-press  response was  initially 
accomplished by  training  rats to bar-press for  water. Can- 
nulas  were  then  implanted  in  the  external  jugular  vein 
according to procedures described by Weeks [21]. Self-ad- 
ministration  testing  began with  a  16-h nocturnal  session 
0006-8993/97/$17.00  Copyright  0  1997  Elsevier  Science  B.V.  All rights  reserved. 
PII  SOOOS-8993(96)01414-X S.D. Glick  et al. /Brain  Research 749 (1997) 340-343  341 
followed  by daily  l-h  sessions, 5 days (Monday-Friday)  a 
week. A  lever-press response produced a 10 pl  infusion of 
drug solution (0.01 mg of morphine sulfate) in about 0.2 s. 
Since all rats generally weighed 250 +  20 g, each response 
delivered approximately  0.04 mg/kg  of morphine. Experi- 
ments to  assess the effects  of  ibogaine  (40  mg/kg,  i.p.), 
alone  or  in  combination  with  a  K-antagonist  (norbinal- 
torphimine,  norBN1;  10 mg/kg,  s.c.)  and/or  a  NMDA 
agonist (N-methyl-D-aspartate,  NMDA;  20  mg/kg,  i.p.), 
were begun when  baseline self-administration  rates stabi- 
lized  (less than  10%  variation  from  one day  to  the next 
across 5  days),  usually  after  2  weeks  of  testing.  Each 
treatment was tested in a different  group of rats; injections 
were  made  on  Wednesdays. Ibogaine  and  NMDA  were 
administered  15 min  before  a self-administration  session, 
whereas norBN1 was administered 2 h before the same test 
session. 
The effects of the same treatments on morphine-induced 
locomotor  stimulation  were studied using the same proce- 
dures previously  employed with  ibogaine alone [ 141.  Loco- 
motor  activity  was  assessed using  cylindrical  photocell 
activity  cages (60 cm,  three crossing beams) interfaced to 
an IBM-compatible  486 computer. Different  groups of rats 
were  treated  with  different  combinations  of  norBN1, 
NMDA,  ibogaine or saline (norBN1 administered  1 h prior 
to  co-administration  of  ibogaine  and  NMDA  or  saline), 
and  19 h later, injected  with  morphine  sulfate (5 mg/kg, 
i.p.)  immediately  before  being  placed  into  the  activity 
cages. Locomotor  activity  was  monitored  for  1 h  there- 
after. 
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The microdialysis  procedures used to assess  the effects 
of the same treatments on extracellular levels of dopamine 
and its  metabolites in  the striatum have been used exten- 
sively in this laboratory, e.g., [4,5,8]. Briefly,  under pento- 
barbital anesthesia,  rats were implanted stereotaxically with 
guide cannulas over the striatum so that, when inserted, the 
tips of the dialysis probes would be located in the striatum 
(rostral,  + 0.5 mm; lateral,  f  2.9 mm; ventral,  -  7.0 mm) 
[12]. The cannula was fixed firmly  in the skull  with  dental 
cement. 
At  least 4  days after  surgery,  a  rat  was  placed  in  a 
dialysis chamber, a cylindrical  (30 cm diameter) Plexiglas 
cage providing  free access  to food and water. The probe (3 
mm;  CMA  8309563)  was  then  lowered  into  the  guide 
cannula.  The  dialysis  probe  was  continuously  perfused 
with  a solution  containing  146 mM  NaCl,  2.7  mM  KCl, 
1.2 mM  CaCl,  and  1.0 mM  MgCl,  at  a flow  rate of  1 
pl/min.  On the next morning (15-20  h later), the dialysis 
experiment  was  carried  out  on  a  freely  moving  animal. 
NorBNI  or saline was administered at time  0, and NMDA 
or  saline,  and  ibogaine  were  co-administered  2  h  later. 
Twenty-minute  fractions were collected in vials containing 
2 ~1 of  1.1 N perchloric  acid solution (containing  5 mg/l 
EDTA  and 5 mg/l  sodium metabisulfite).  Upon  comple- 
tion  of  an  experiment,  rats  were  killed  and  histological 
analysis of  each brain  was performed  to  verify  the  loca- 
tions of the probes. 
Perfusate samples were analyzed by HPLC  with  electro- 
chemical detection. The HPLC consisted of a Waters pump 
(model  510)  a WISP  autosampler (model  712)  a Phase 
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Fig.  1. Partial antagonism by a combination  of  NMDA  and norBN1 of  the effects of  ibogaine (IBO,  40 mg/kg,  i.p.) on morphine (0.04  mg/kg/infusion) 
self-administration  (N  =  6 rats/group).  lbogaine (40 mg/kg,  i.p.)  and NMDA  (20 mg/kg,  i.p.) were administered  15 min  before the test session on Day  1 
whereas norBiu’1 (10 mg/kg,  s.c.) was administered  2 h before the same test session; the NMDA  +  norBN1 +  IBO  gluup  was significantly  different  from 
the other ibogaine groups on Day  1 ( l  ,  P < 0.02;  see text). 342  S.D. Glick  et al. /Brain  Research 749 (19971 340-343 
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Fig.  2. Effects  of  norBN1 (10 mg/kg,  s.c.) and NMDA  (20 mg/kg,  i.p.l 
on ibogaine (40 mg/kg,  i.p.)  antagonism of morphine-induced  (5 mg/kg, 
i.p.)  locomotor  activity  (N  =  8 rats/group).  NorBNI  or saline was admin- 
istered 1 h before NMDA  and ibogaine (or saline controls).  The morphine 
challenge  was  administered  19 h  after  ibogaine  and/or  NMDA.  The 
Sal-Sal-Ibo,  the  Sal-NMDA-IBO  and the  norBNI-Sal-IBO  groups  were 
all  significantly  different  ( * ,  P < 0.05)  from  the Sal-Sal-Sal  group.  The 
norBNI-NMDA-IBO  group  was not  significantly  different  from  the Sal- 
Sal-Sal group (P  >  0.05). 
Separation Spherisorb C-18  column  (S3 ODS2;  10 cm X 
4.6 mm)  and a Waters detector (model  464).  The mobile 
phase consisted of  6.9 g/l  sodium  monobasic phosphate, 
450 mg/l  heptane sulfonic  acid, 80 mg/l  disodium EDTA, 
and  110 ml/l  methanol;  the  solution  was  adjusted with 
HCl  to pH  3.7 and was pumped at a rate of  1.2 ml/min. 
Chromatograms  were  processed  using  Hewlett-Packard 
HPLC  2D Chem Station software. 
Fig.  1 shows the  morphine  self-administration  results. 
The combination  of  NMDA  and norBN1 significantly  an- 
tagonized  the  effect  of  ibogaine  on  Day  1  (significant 
treatment X  days interaction,  ANOVA,  P < 0.01;  NMDA 
+  norBN1 + ibogaine  significantly  different  from  ibo- 
gaine,  NMDA  + ibogaine,  and  norBN1 + ibogaine,  P < 
0.02, Newman-Keuls)  but  not  thereafter. Ibogaine  alone, 
as well  as with  NMDA  or  norBN1,  significantly  reduced 
morphine self-administration  on Days  1 and 2 (P < 0.O.S 
0.001)  Not  shown  are  data  from rats administered  saline 
(i-n  place of ibogaine) together  with NMDA, norBNI or the 
combination:  there was no effect of these  treatments  alone 
on morphine self-administration. 
Fig.  2  shows  the  locomotor  activity  results.  Ibogaine 
inhibition  of morphine-induced hyperactivity  (ANOVA  and 
LSD  tests,  P < 0.05)  was  partially  antagonized  by  the 
combination  of norBN1 and NMDA.  The norBNI-NMDA- 
IBO  group  did  not  differ  (LSD  test,  P >  0.05)  from  the 
control  group (Sal-Sal-Sal). 
Fig. 3 shows the microdialysis  results. The inhibition  of 
dopamine release by  ibogaine  as well  as the ibogaine-in- 
duced increases in DOPAC  and HVA  were antagonized by 
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Fig.  3.  Antagonism  of  ibogaine-induced  (40  mg/kg,  i.p.1  changes in 
striatal dopamine, DOPAC  and HVA  by norBNI  and/or  NMDA.  NorBNI 
(10  mg/kg,  s.c.) or  saline was administered  at time  0 and NMDA  (10 
mg/kg,  i.p.)  or  saline, and ibogaine (40 mg/kg,  i.p.)  were co-adminis- 
tered 2 h  later  (N  =  6 for  the norBNI-NMDA-IBO  group  and 4  for  a11 
other groups). The combination  of norBN1 + NMDA  as well  as each drug 
alone significantly  (P  < 0.05)  attenuated the decrease in  dopamine (A) 
and the increase in DOPAC  (B);  the combination  of norBN1 + NMDA  as 
well  as NMDA  alone significantly  (P  < 0.05)  attenuated the increase in 
HVA  (Cl. 
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the combination  of norBNI  and NMDA  as well  as bv each 
drug alone (ANOVA,  P  < 0.05). Although  not significant 
from  either  drug  alone,  the  combination  of  norBN1  and 
NMDA  appeared to  be  the  most  effective  antagonist of 
ibogaine. 
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All  of  these data together indicate  that  both  K-opioid 
agonist  and  NMDA  antagonist  actions  of  ibogaine  con- 
tribute  to  its  putative  anti-addictive  effects. However,  the 
antagonism of ibogaine by the combination of norBN1 and 
NMDA  in  the behavioral  studies was  sometimes incom- 
plete,  suggesting  that  another  (i.e.,  a  third)  mechanism 
(e.g., serotoninergic) [lo]  may be involved,  or the dose of 
norBN1 and/or  NMDA  may not have been optimal.  With 
regard to the morphine self-administration  data in particu- 
lar, ibogaine and/or  noribogaine or another active metabo- 
lite may have been present at a time (i.e., Day 2) when part 
of  the combined  treatment  (i.e.,  NMDA)  was  no  longer 
present. 
Both  K-agonists  and  NMDA  antagonists  have  been 
reported to  decrease dopamine release in  the nucleus ac- 
cumbens. Because their  sites of  action  are different  their 
effects  may  be additive.  K-Agonists  exert their  inhibitory 
action  in  the nucleus accumbens, possibly  by  interacting 
with  K-opioid receptors located on dopaminergic terminals 
[19],  while  NMDA  antagonists block  the excitatory  tonic 
control  that glutamate exerts on dopamine neurons in  the 
ventral  tegmental  area  [20].  In  addition,  cortical  gluta- 
matergic neurons may be under K-opioid inhibition  [2,18], 
possibly increasing the efficacy  of the combined actions. It 
appears  that  the  combination  of  these  actions  confers 
ibogaine with  a somewhat unique pharmacological profile. 
Together with  data showing that ibogaine is sequestered  in 
fat [7], the present data are consistent with  the hypothesis 
that ibogaine’s long-term effects may be mediated by slow 
release from  fat  tissue,  conversion  to  noribogaine,  and 
binding  of  both ibogaine and noribogaine to  K-opioid and 
NMDA  receptors. 
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